Sylvester Comprehensive Cancer Center

  • SPN-00900 - Bradley, Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20211051

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Geron

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat and in Combination with Ruxolitinib in Patients with Myelofibrosis.

    Eligibility Criteria - NCT05371964 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220775 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20220775

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Sumitomo Dainippon Pharma Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Phase I/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

    Eligibility Criteria - NCT04176198 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201405 - Chandhok Namrata

  • Investigator:
    Namrata Chandhok
    RCname Email

    Coordinator:

    IRB: 20201405

    SDG: Leukemia/heme
    Disease Site(s):

    Multiple

    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester

    Title:

    The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Eligibility Criteria - NCT03953898 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220185 - Chandhok Namrata

  • Investigator:
    Namrata Chandhok
    RCname Email

    Coordinator:

    IRB: 20220185

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Syntrix Pharmaceuticals

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome

    Eligibility Criteria - NCT04245397 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201503 - Sekeres Mikkael

  • Investigator:
    Mikkael Sekeres
    RCname Email

    Coordinator:

    IRB: 20201503

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: SCCC

    Enrolling Sites:

    Cleveland Clinic Ohio
    Sylvester

    Title:

    A multicenter, Phase Ib/II study that combines Luspatercept and Lenalidomide (L2) in lower-risk, non-del(5q) MDS Patients

    Eligibility Criteria - NCT04539236 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220383 - Sekeres Mikkael

  • Investigator:
    Mikkael Sekeres
    RCname Email

    Coordinator:

    IRB: 20220383

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Rigel Pharmaceuticals

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Relapsed/Refractory/Resistant to Prior Therapies

    Eligibility Criteria - NCT05308264 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230058 - Sekeres Mikkael

  • Investigator:
    Mikkael Sekeres
    RCname Email

    Coordinator:

    IRB: 20230058

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Keros Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

    Eligibility Criteria - NCT04419649 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230791 - Sekeres Mikkael

  • Investigator:
    Mikkael Sekeres
    RCname Email

    Coordinator:

    IRB: 20230791

    SDG: Leukemia/heme
    Disease Site(s):

    Multiple

    Sponsor: NextCure

    Enrolling Sites:

    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

    Eligibility Criteria - NCT05787496 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230752 - Soff Gerald

  • Investigator:
    Gerald Soff
    RCname Email

    Coordinator:

    IRB: 20230752

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: DANA-FARBER CANCER INSTITUTE

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients with Gastrointestinal Malignancies

    Eligibility Criteria - NCT05772546 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230812 - Traeger Lara

  • Investigator:
    Lara Traeger
    RCname Email

    Coordinator:

    IRB: 20230812

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, not otherwise specified

    Sponsor: MASSACHUSETTS GENERAL HOSPITAL

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia - SCOPE Leukemia

    Eligibility Criteria - NCT05237258 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230633 - Venugopal Sangeetha

  • Investigator:
    Sangeetha Venugopal
    RCname Email

    Coordinator:

    IRB: 20230633

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: Oryzon Genomics SA

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    An escalation/expansion, Open label, Multicenter study of iadademstat and gilteritinib in patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+): The FRIDA Study/ CL04-ORY-1001

    Eligibility Criteria - NCT05546580 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190675 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20190675

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients with Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

    Eligibility Criteria - NCT04365179 *This information has been extracted from " www.clinicaltrials.gov"

  • INCB057643 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20200314

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Incyte Corporation

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

    Eligibility Criteria - NCT04279847 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211090 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20211090

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: Sumitomo Dainippon Pharma Oncology

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients With and Without Mixed Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation

    Eligibility Criteria - NCT04988555 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220275 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20220275

    SDG: Leukemia/heme
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: Janssen

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years* with Newly-diagnosed Philadelphia-negative ALL

    Eligibility Criteria - NCT04817761 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221233 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20221233

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: University of Colorado

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (aged 18-59) with Acute Myeloid Leukemia

    Eligibility Criteria - NCT03573024 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230424 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20230424

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: POLARIS PHARMACEUTICALS

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    Phase IA/B Combination Study of ADI-PEG 20, Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia (AML)

    Eligibility Criteria - NCT05001828 *This information has been extracted from " www.clinicaltrials.gov"